.abbott Domain Information
Applicant Full Legal Name
Abbott Laboratories
Legal Establishment
Corporation
Applicant Address
100 Abbott Park Road
Abbott Park Illinois 60064
US
State Jurisdiction
Illinois, USA
Applicant Website
http://www.abbott.com
Applied for gTLD
ABBOTT
Domain Registration Status
Closed
Mission/Purpose of Domain Extension
18.1 Mission and Purpose of .ABBOTT Abbott Laboratories ("Abbott") is a global, diversified healthcare company devoted to the discovery, development, manufacture, and marketing of pharmaceuticals, nutritional products, and medical products including devices, diagnostic tests, and instruments.... Read more
18.1 Mission and Purpose of .ABBOTT
Abbott Laboratories ("Abbott") is a global, diversified healthcare company devoted to the discovery, development, manufacture, and marketing of pharmaceuticals, nutritional products, and medical products including devices, diagnostic tests, and instruments. Abbott has sales, manufacturing, research and development, and distribution facilities around the world and is well-recognized for its global reach. Abbott employs over 90,000 people and has an online presence in over 75 countries. Its online content is accessible in the .COM gTLD and also in multiple ccTLDs. A sample of the ccTLDs in which Abbott posts content is as follows: .COM.AR, .COM.AU, .COM.CN, .DK, .FR, .DE, .CO.IN, .IE, JP, .NO, .ES, .CO.UK, .CA, and .US.
Abbott Laboratories manufactures and distributes numerous products around the world in the following categories: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. For more information, see: http://www.abbottinvestor.com/.
Through a unified corporate approach, Abbott intends to submit two gTLD applications for the .ABBOTT and .ABBVIE gTLDs.
The intended future mission and purpose of the .ABBOTT gTLD is to serve as a trusted, hierarchical, and intuitive namespace provided by Abbott and its subsidiaries for its consumers. Abbott Laboratories is the designated entity to file this application and bring the .ABBOTT gTLD to market. Therefore, although Abbott is committed to moving forward with the .ABBOTT gTLD application, at the time of filing Abbott does not believe that there has been enough time or market information available to fully analyze and evaluate all potential use case options. Thus, Abbott is planning for a limited use of the .ABBOTT gTLD initially, with the possibility of expanding as market information becomes available and Abbott's digital strategy develops.
Abbott will be analyzing and evaluating other .BRAND gTLD applications, as well as general market adoption, to determine short- and long-term potential best use case options to more effectively serve and enhance Abbott's online strategy as a leading global diversified healthcare company.
Abbott intends to initially limit registration and use of domain names within the .ABBOTT gTLD to Abbott and its qualified subsidiaries and affiliates. This initial limited use will allow Abbott to establish its operations and achieve full sustainability. This limited distribution, coupled with the other requirements set forth in Specification 9 of the template Registry Agreement, is intended to exempt Abbott from its annual Code of Conduct Compliance requirements.
After Stage 3 (below), Abbott will evaluate whether opportunities exist to carry out the business strategy for the .ABBOTT gTLD through expansion that continues the sustainable operations of the registry through fee-based registrations to parties other than Abbott and its qualified subsidiaries and affiliates.
Abbott currently plans a four-stage rollout for the .ABBOTT gTLD:
1. Stage 1
The initial stage of implementation of the gTLD will involve Abbott registering a limited number of .ABBOTT second-level domain names.
This initial use will provide Abbott's IT and security personnel the time to run a number of tests to ensure seamless and secure access using the .ABBOTT gTLD domain names, interoperability with various software and Web-based applications, and unbroken and secure use of all names. This initial allocation will also allow the appropriate Abbott staff to coordinate with the internal and external staff responsible for the application, delegation, and setup phases of the .ABBOTT gTLD to ensure a proper transition from delegation to full operation.
2. Stage 2
Once all testing has been successfully completed, Abbott will begin allocating domain names in the .ABBOTT gTLD for more widespread internal corporate use. During this same period of time, Abbott will begin evaluating strategies to potentially migrate traffic away from its current network of second-level domain names, which are registered in a variety of TLDs, to Abbott's new gTLDs.
It is in Stage 2 that Abbott will evaluate expanding the operations of the gTLD to permit registration by other registrants, such as licensees or other strategic parties. Should an assessment of its expansion strategy lead to a decision to extend registration rights to other parties, Abbott is currently planning for this expansion to take place during Stage 3. However, any expansion would be dependent upon a review of Specification 9 (Registry Code of Conduct) set forth in the template Registry Agreement to ensure compliance with Abbott's business model.
3. Stage 3
Depending upon the analysis of the evaluations undertaken in stage two, Abbott may begin to implement the migration of Internet traffic away from the TLDs in which Abbott's domain names are currently registered, and toward the .ABBOTT gTLD. It is in this stage that Abbott also may implement its decision to extend registration rights to licensees or strategic parties depending upon compliance with Specification 9 as noted above. The dates of such expansion are subject to change depending upon business, strategic, and industry factors at the time.
After consideration of the following factors: analysis of Abbott's existing domain name portfolio; internal analysis of marketing initiatives; and the fact that Abbott will have full control over the number of registrations in the .ABBOTT gTLD namespace, Abbott is confident that the number of domain name registrations will be less than 10,000 in the first five years of operation.
4. Stage 4
Based on its experience with any expansion implemented in Stage 3, Abbott will assess whether its business plan and expansion strategy should be augmented by extending registration rights to a broader class of licensees, potentially including customers of Abbott. It is anticipated by Abbott that changes to the domain name industry, and particularly the impact of .BRAND gTLDs, will take at least five years to be realized and assessed. Any decision to expand the gTLDs beyond corporate, qualified subsidiary and affiliate, and licensee use will take into account this experience as well as the technical analysis of potential expansion.
The potential use of the .ABBOTT gTLD by Abbott and its various business segments will also be driven by Abbott's future business strategies as identified in its annual report and investor filings, see: http://www.abbottinvestor.com/.
Utilizing current projections based upon Abbott's existing businesses, future business plans, current domain name portfolio, and other strategic factors, Abbott estimates that second-level domain name registrations will be in line with the projections set forth in the financial template provided in response to Question 46 of this application.
×
Abbott Laboratories ("Abbott") is a global, diversified healthcare company devoted to the discovery, development, manufacture, and marketing of pharmaceuticals, nutritional products, and medical products including devices, diagnostic tests, and instruments. Abbott has sales, manufacturing, research and development, and distribution facilities around the world and is well-recognized for its global reach. Abbott employs over 90,000 people and has an online presence in over 75 countries. Its online content is accessible in the .COM gTLD and also in multiple ccTLDs. A sample of the ccTLDs in which Abbott posts content is as follows: .COM.AR, .COM.AU, .COM.CN, .DK, .FR, .DE, .CO.IN, .IE, JP, .NO, .ES, .CO.UK, .CA, and .US.
Abbott Laboratories manufactures and distributes numerous products around the world in the following categories: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. For more information, see: http://www.abbottinvestor.com/.
Through a unified corporate approach, Abbott intends to submit two gTLD applications for the .ABBOTT and .ABBVIE gTLDs.
The intended future mission and purpose of the .ABBOTT gTLD is to serve as a trusted, hierarchical, and intuitive namespace provided by Abbott and its subsidiaries for its consumers. Abbott Laboratories is the designated entity to file this application and bring the .ABBOTT gTLD to market. Therefore, although Abbott is committed to moving forward with the .ABBOTT gTLD application, at the time of filing Abbott does not believe that there has been enough time or market information available to fully analyze and evaluate all potential use case options. Thus, Abbott is planning for a limited use of the .ABBOTT gTLD initially, with the possibility of expanding as market information becomes available and Abbott's digital strategy develops.
Abbott will be analyzing and evaluating other .BRAND gTLD applications, as well as general market adoption, to determine short- and long-term potential best use case options to more effectively serve and enhance Abbott's online strategy as a leading global diversified healthcare company.
Abbott intends to initially limit registration and use of domain names within the .ABBOTT gTLD to Abbott and its qualified subsidiaries and affiliates. This initial limited use will allow Abbott to establish its operations and achieve full sustainability. This limited distribution, coupled with the other requirements set forth in Specification 9 of the template Registry Agreement, is intended to exempt Abbott from its annual Code of Conduct Compliance requirements.
After Stage 3 (below), Abbott will evaluate whether opportunities exist to carry out the business strategy for the .ABBOTT gTLD through expansion that continues the sustainable operations of the registry through fee-based registrations to parties other than Abbott and its qualified subsidiaries and affiliates.
Abbott currently plans a four-stage rollout for the .ABBOTT gTLD:
1. Stage 1
The initial stage of implementation of the gTLD will involve Abbott registering a limited number of .ABBOTT second-level domain names.
This initial use will provide Abbott's IT and security personnel the time to run a number of tests to ensure seamless and secure access using the .ABBOTT gTLD domain names, interoperability with various software and Web-based applications, and unbroken and secure use of all names. This initial allocation will also allow the appropriate Abbott staff to coordinate with the internal and external staff responsible for the application, delegation, and setup phases of the .ABBOTT gTLD to ensure a proper transition from delegation to full operation.
2. Stage 2
Once all testing has been successfully completed, Abbott will begin allocating domain names in the .ABBOTT gTLD for more widespread internal corporate use. During this same period of time, Abbott will begin evaluating strategies to potentially migrate traffic away from its current network of second-level domain names, which are registered in a variety of TLDs, to Abbott's new gTLDs.
It is in Stage 2 that Abbott will evaluate expanding the operations of the gTLD to permit registration by other registrants, such as licensees or other strategic parties. Should an assessment of its expansion strategy lead to a decision to extend registration rights to other parties, Abbott is currently planning for this expansion to take place during Stage 3. However, any expansion would be dependent upon a review of Specification 9 (Registry Code of Conduct) set forth in the template Registry Agreement to ensure compliance with Abbott's business model.
3. Stage 3
Depending upon the analysis of the evaluations undertaken in stage two, Abbott may begin to implement the migration of Internet traffic away from the TLDs in which Abbott's domain names are currently registered, and toward the .ABBOTT gTLD. It is in this stage that Abbott also may implement its decision to extend registration rights to licensees or strategic parties depending upon compliance with Specification 9 as noted above. The dates of such expansion are subject to change depending upon business, strategic, and industry factors at the time.
After consideration of the following factors: analysis of Abbott's existing domain name portfolio; internal analysis of marketing initiatives; and the fact that Abbott will have full control over the number of registrations in the .ABBOTT gTLD namespace, Abbott is confident that the number of domain name registrations will be less than 10,000 in the first five years of operation.
4. Stage 4
Based on its experience with any expansion implemented in Stage 3, Abbott will assess whether its business plan and expansion strategy should be augmented by extending registration rights to a broader class of licensees, potentially including customers of Abbott. It is anticipated by Abbott that changes to the domain name industry, and particularly the impact of .BRAND gTLDs, will take at least five years to be realized and assessed. Any decision to expand the gTLDs beyond corporate, qualified subsidiary and affiliate, and licensee use will take into account this experience as well as the technical analysis of potential expansion.
The potential use of the .ABBOTT gTLD by Abbott and its various business segments will also be driven by Abbott's future business strategies as identified in its annual report and investor filings, see: http://www.abbottinvestor.com/.
Utilizing current projections based upon Abbott's existing businesses, future business plans, current domain name portfolio, and other strategic factors, Abbott estimates that second-level domain name registrations will be in line with the projections set forth in the financial template provided in response to Question 46 of this application.
×